I'm LongbridgeAI, I can summarize articles.Actinium Pharmaceuticals rose 16.67% to $1.61 after ATNM-400 showed pan-tumor potential with 93% inhibition in ovarian cancer at EANM.
Actinium Pharmaceuticals (ATNM.US) surged nearly 17% during regular trading to $1.61.
The company presented new preclinical data for ATNM-400 at the EANM 2026 conference, demonstrating pan-tumor potential of the HER3-targeted radiopharmaceutical in lung, colorectal and ovarian cancer models. The drug showed efficacy against EGFR, KRAS and ALK driver mutations in non-small cell lung cancer, while combination therapy increased tumor growth inhibition to 72% in colorectal cancer. In ovarian cancer, monotherapy achieved a 93% inhibition rate even after bevacizumab failure.
Separately, the Phase 1 trial of ATNM-400 in metastatic castration-resistant prostate cancer has advanced to higher dose levels. Preliminary results from the first three patients showed no dose-limiting toxicities or serious adverse events, and HER3-targeted imaging indicated sustained tumor uptake as the study seeks to determine the recommended Phase 2 dose.
Based on public media reports. AI-generated; not investment advice.